<DOC>
	<DOC>NCT02837757</DOC>
	<brief_summary>Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. The objective of this study is to investigated the influence of everolimus immune modulation on antitumor efficacy .</brief_summary>
	<brief_title>Everolimus Modulation of Anti-tumor T CD4 Immune Responses</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Performance status ECOGWHO 0, 1 or 2 Metastatic renal cancer Patient candidate to everolimus treatment signed written informed consent fertile women with adequate contraception during the study and until 8 weeks after stopping treatment Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (prednisone or prednisolone â‰¤ 10 mg/day is allowed) History of immune deficiency Hypersensitivity against rapamycin and derived Prior history of other malignancy except for: basal cell carcinoma of the skin, cervical intraepithelial neoplasia and other cancer curatively treated with no evidence of disease for at least 5 years Active autoimmune diseases, HIV, hepatitis C or B virus Patients with any medical or psychiatric condition or disease, Patients under guardianship, curatorship or under the protection of justice.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>